by Vora Corporate Finance | Dec 16, 2024 | Insights, Private Equity & IPO
Transaction: Beta Drugs, a vertically integrated cancer firm, raised INR 117 crore in a funding round led by HealthQuadFund II, Inti Capital and Generational Capital for a minority stake in the company. The stake has been given through preferential allotment of...
by Vora Corporate Finance | Dec 16, 2024 | Insights, Merger & Acquisitions
Transaction: Ahead of the merger, Aster will purchase a 5.0% stake in Quality Care from Blackstone and TPG in consideration of primary share issuance by Aster for a 3.6% stake. Post the initial share acquisition, Quality Care will be merged into Aster by way of a...
by Vora Corporate Finance | Dec 16, 2024 | Insights
The BSE Sensex closed at 79,803 up by 0.52% and the Nifty 50 closed at 24,131 down by 0.31% in November 2024, driven by concerns over stretched valuations, weak performance by Indian Inc in Q2 and persistent selloffs by foreign investors. From a sector perspective,...
by Vora Corporate Finance | Dec 16, 2024 | Insights, Private Equity & IPO
There were 08 main board IPOs in November 2024 of Afcons Infrastructure Limited, Sagility India Limited, Swiggy Limited, ACME Solar Holdings Limited, Niva Bupa Health Insurance Limited, Zinka Logistics Solutions Limited, NTPC Green Energy Limited and Enviro Infra...
by Vora Corporate Finance | Dec 16, 2024 | Insights
The Monetary Policy Committee (MPC) of the RBI, which met in Mumbai in December 2024, kept the Repo rate unchanged at 6.5% in a majority 4-2 decision. This is the eleventh consecutive monetary policy, over 22 months, which has left the Repo rate unchanged. The MPC has...
